Beta: Sign in
Shares outstandingAs of 2026-07-31 · 2 filed common classes summed: 575.00M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.25%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 2.07%
Short ratioDays to cover, as published by FINRA: 5.05
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 45.60%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 41.70%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Profitability

Gross margin: —
Operating marginTTM to Jun 26: 59.61%
Net margin: —
EBITDA marginTTM to Jun 26: 59.80%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: 9.95%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: 4.26%

Growth

Revenue growth (annual YoY): 5.06%
Revenue growth (latest qtr YoY): 16.50%
Revenue growth (fwd): Sign in
Net income growth (annual YoY)FY Dec 25 vs FY Dec 24: -10.25%
Net income growth (latest qtr YoY): -44.42%
EPS growth (fwd): Sign in
Net income growth (QoQ): -93.93%

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

1.86

EPS (fwd)

Financial health

Cash & equivalentsas of Jun 26: $811.98M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $8.96B
Debt / equityas of Jun 26: 131.16%
Current ratioas of Jun 26: 2.80
Quick ratio: —
Operating cash flowTTM to Jun 26: $2.97B
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: $2.97B
TTM revenue / diluted shareDiluted, TTM to Jun 26: 4.55

RPRX stock Statistics — Royalty Pharma plc filings, insiders & smart money · Instaport